Breast Cancer Awareness Month : Pioneering Detection with Precision

At Diagnostic BioSystems, we’re proud to support the fight against breast cancer (BrCa) by providing reliable immunohistochemistry (IHC) antibodies and reagents that enable accurate, timely diagnosis and provide information of prognosis and therapeutics. IHC plays a crucial role in identifying a various types of breast cancers. The key IHC biomarkers include Estrogen receptor (ER), Progesterone receptor (PR), human epidermal growth factor receptor-2/c-erB-2/Oncoprotein (HER2Neu), and Ki67 (cell proliferation index) among other biomarkers. The IHC testing by the four biomarkers establishes personalized therapeutic plans for patients with breast cancers worldwide.

Role of IHC:

For diagnosis, prognosis, and treatment of BrCa, immunohistochemically it starts with the detection of ER, PR, HER2Neu, and Ki67 by IHC to differentiate the types of breast cancers and to determine the prognosis and treatment protocols. There are approximately 15%-20% of breast cancers that are characterized with cancer cells not being immunoreactive to antibodies against ER, PR, and Her2Neu. They are referred to as triple negative BrCa (TNBrCa) or basal like breast carcinoma. GATA3 is a much-often used IHC biomarker for making diagnosis of breast cancer, although it is not very sensitive and not able to tell breast cancer from bladder urothelial cancer.

Trichorhinophalangeal syndrome 1 (TRPS1) is a highly sensitive marker for breast cancer and relatively specific, by not expressing in bladder urothelial cancer. The combination of GATA3 and TRPS1 would be the excellent combination to make a diagnosis sensitively and specifically. The two biomarkers are now available at Diagnostic BioSystems.

Explore DBS’s highly sensitive and reliable markers for your breast cancer cases.

Together, we can make early detection more effectively by saving lives, one diagnosis at a time.

PDF: https://bit.ly/DBS-BreastPanel
Flipbook: https://bit.ly/DBS-FlipBook-BreastCancerAntibodyPanel

#BreastCancerAwareness #IHCSavesLives #AdvancingDiagnostics #PrecisionMedicine
#SupportingSurvivors